CellProthera products

The unique therapeutic approach proposed by CellProthera is protected by various patents. It requires a simple blood sampling best performed within 2 weeks following a severe AMI. The sampling occurs after a treatment period using GCSF in order to mobilize the patient’s own stem cells into the blood flow. The patient’s blood sample is then forwarded to a local certified Cell Therapy center and processed in our proprietary automated device StemXpand® using our standard kit StemPack® for the preparation of the final graft product ProtheraCytes®.